An endoscopic response is a decrease from baseline CDEIS score of at least 4 or 5 points. The CDEIS has been used in trials of corticosteroids, thiopurines, and TNF antagonists. In the MUSIC (Endoscopic Mucosal Improvement in Patients With Active Crohn’s Disease Treated With Certolizumab Pegol) study of certolizumab pegol in Crohn’s disease,
maintenance of improvement between weeks 10 and 54, based on individual patient data, was found in 70% of those who responded (decline in CDEIS >5) and those with complete remission (CDEIS<3), and in more than 40% of those with remission (CDEIS<6).43 The SES-CD (Table 6) correlates Dabrafenib well with the CDEIS, with a correlation coefficient r = 0.920
and excellent interobserver reliability (k coefficients 0.791–1.000). This score was developed to meet the need for a reliable, easy-to-use endoscopic scoring instrument for Crohn’s disease, one that by contrast would be less complex than the CDEIS. Selected endoscopic parameters (ulcer size, ulcerated and affected surfaces, stenosis) were scored from 0 to 3, whereby SES-CD = 0 equates to absence of ulcers. 41 No cutoff values have been determined for the SES-CD, and there is no definition of mucosal healing. The Rutgeerts Postoperative Endoscopic Index (Table 7) determines the severity of endoscopic disease recurrence at the anastomosis and in the neoterminal ileum after ileocolic resection.42 and 44 GDC-0980 concentration The severity of endoscopic recurrence predicts clinical recurrence, so it has gained popularity.42 In the year after ileocolic resection, patients with a Rutgeerts score of 0 or 1 have a low risk of clinical recurrence (20% at 3 years follow-up) compared with Y-27632 2HCl those patients who have a score of grade 3 or 4 (92% at 3 years follow-up). Level 2 is associated with an intermediate risk of clinical recurrence, but the definition of grade 2 is more subjective and is exposed to variability. This index has also been incorporated into
a randomized clinical trial. In the Post Operative Crohn’s Endoscopic Recurrence study, it was shown that treating according to the risk of recurrence with a 6-month postoperative colonoscopy and treatment step up for those who had a Rutgeerts score ≥i2, is significantly superior to drug therapy alone in preventing postoperative recurrence.45 The colonoscopic assessment of mucosal healing has proved increasingly important in the management of both UC and Crohn’s disease. All clinicians should strive for this goal. There is evidence for a decrease in corticosteroid use, decreased hospitalization, an increase in sustained remission, and a decrease in the need for surgery. Further advancements with surrogate noninvasive markers for mucosal healing may help to overcome existing limitations and need for colonoscopy.